Hemostatic and Tissue Sealing Agents

Hemostatic and Tissue Sealing Agents Market Outlook

The global hemostatic and tissue sealing agents market is projected to reach approximately USD 5.2 billion by 2035, growing at a CAGR of around 7.2% during the forecast period from 2025 to 2035. The increasing prevalence of surgical procedures, coupled with the demand for advanced medical devices, is driving this growth. Factors such as the rising incidence of trauma cases, advancements in surgical techniques, and a growing geriatric population requiring surgical interventions are also contributing significantly to market expansion. Furthermore, heightened awareness regarding wound management and patient safety has led to increased investments in hemostatic and sealing technologies. This robust demand is further complemented by the continuous innovations and product developments in the healthcare sector.

Growth Factor of the Market

One of the primary growth factors driving the hemostatic and tissue sealing agents market is the rising volume of surgeries performed across various medical disciplines, including cardiovascular, orthopedic, and general surgeries. The growing recognition of the importance of hemostatic agents in minimizing blood loss during surgical procedures enhances their adoption by healthcare professionals and institutions. Additionally, the increasing incidence of chronic conditions such as diabetes, which often requires surgical interventions, is further propelling market growth. Advances in medical technology, including the development of innovative hemostatic products that provide improved efficacy and safety, also contribute significantly to market expansion. Moreover, the growing preference for minimally invasive surgical procedures, which often employ these agents to enhance patient recovery and reduce hospital stays, is an added advantage boosting the market's trajectory.

Key Highlights of the Market

• Significant growth expected in the hemostatic and tissue sealing agents market, driven by technological innovations.
• Rising surgical procedures across various medical specialties fueling demand for effective hemostatic solutions.
• Minimally invasive surgeries promoting the adoption of advanced sealing agents for better patient outcomes.
• Increased investment in healthcare infrastructure and product R&D by key players.
• Growing awareness among healthcare professionals regarding the benefits of these agents in surgical settings.

By Product Type

Topical Hemostats:

Topical hemostats are widely utilized in surgical procedures to control bleeding by promoting clot formation at the site of injury. These agents are often composed of materials that are either absorbable or non-absorbable, and they work by providing a matrix for clot formation or by directly promoting platelet aggregation. The rising incidence of surgical procedures, including elective surgeries, is significantly fueling the demand for topical hemostats. Moreover, advancements in product formulations and the development of new topical agents are expected to further drive market growth within this segment. As healthcare providers increasingly recognize the importance of effective blood loss management, the adoption of these agents in surgical and emergency settings is also on the rise.

Adhesives:

Adhesives play a vital role in various surgical applications, providing not only hemostatic properties but also serving as effective bonding agents for tissue approximation. The growing demand for minimally invasive surgical techniques has enhanced the use of surgical adhesives, as they facilitate quick wound closure without the need for sutures, thereby reducing recovery time. Innovations in adhesive formulations, such as bio-adhesives that are designed to be biocompatible and biodegradable, are gaining traction in the market. Factors such as the increasing prevalence of surgical site infections and the growing emphasis on patient safety and wound healing are propelling the adoption of adhesives in surgical practice.

Sealants:

Surgical sealants are increasingly being utilized to manage bleeding and can act as a barrier to prevent fluid leakage at surgical sites. Their effectiveness in enhancing hemostasis and minimizing complications during surgical procedures is driving their demand. Many sealants are derived from natural and synthetic polymers, providing diverse options for surgeons based on specific procedural needs. The growing trend towards minimally invasive surgeries is a primary driver for the sealants segment, as these agents provide effective solutions to manage bleeding while preserving tissue integrity. Continuous advancements in sealant formulations, aimed at improving adhesion and reducing the risk of adverse reactions, are expected to fuel further growth in this segment.

Gelatins:

Gelatin-based hemostatic agents are popular in surgical settings due to their biocompatibility and ability to promote clot formation. These agents are derived from collagen and are usually processed to create a foam-like structure that can be applied directly to bleeding sites. The increasing demand for biologically derived products in surgery is significantly boosting the gelatin segment. Additionally, the versatility of gelatins in various applications, including orthopedic and cardiovascular surgeries, enhances their market appeal. As the healthcare sector continues to prioritize effective and safe bleeding control methods, the adoption of gelatin-based products is expected to rise substantially in the coming years.

Collagens:

Collagen-based hemostatic agents are gaining prominence due to their natural properties and ability to stimulate the body’s healing process. These agents facilitate hemostasis by providing a scaffold for platelets and promoting the activation of the coagulation cascade. The increasing awareness regarding the benefits of using collagen products in surgical procedures, coupled with the growing prevalence of surgeries, is significantly driving the demand for collagen-based agents. Furthermore, advancements in collagen processing technology are leading to the development of more effective formulations, which is expected to positively impact the market growth within this segment. As healthcare professionals seek reliable solutions for managing bleeding, collagen hemostatic agents are becoming an increasingly attractive option.

By Application

Cardiovascular Surgery:

Cardiovascular surgeries, including coronary artery bypass grafting and valve replacement, often require effective hemostatic agents to manage bleeding and ensure patient safety. The complexity of these procedures necessitates the use of advanced hemostatic and sealing agents that can effectively control blood loss and promote healing. As the prevalence of cardiovascular diseases continues to rise globally, the demand for hemostatic agents in this application segment is expected to grow significantly. The continuous advancements in surgical techniques and the increasing focus on patient outcomes further enhance the need for effective solutions in cardiovascular surgery, making this segment a key area for market growth.

General Surgery:

The general surgery segment encompasses a wide range of surgical procedures, from appendectomies to gastrointestinal surgeries. The need for hemostatic agents in general surgery is driven by the increasing number of surgical interventions performed annually. Surgeons rely on effective hemostatic products to minimize blood loss and enhance patient recovery times. Furthermore, the rising trend of outpatient surgeries and minimally invasive techniques is fostering the adoption of advanced hemostatic solutions in this segment. The growing emphasis on quick recovery and reduced postoperative complications also contributes to the increasing utilization of hemostatic agents in general surgery.

Orthopedic Surgery:

Orthopedic surgeries often involve significant trauma and bleeding, necessitating the use of effective hemostatic agents to control blood loss and promote healing. The increasing prevalence of orthopedic conditions, driven by an aging population and a rise in sports-related injuries, is propelling the demand for hemostatic solutions in this application area. Surgeons are increasingly adopting innovative sealing and hemostatic products to ensure optimal patient outcomes during procedures such as joint replacements and fracture repairs. This growing trend towards advanced hemostatic agents in orthopedic surgery is expected to positively influence market growth in the coming years.

Neurosurgery:

Neurosurgery is a highly specialized field that often encounters significant challenges related to bleeding and cerebrospinal fluid leaks. Effective hemostatic agents are essential for managing these complications and ensuring patient safety during intricate procedures. The rising number of neurosurgical procedures, driven by an increase in neurological disorders, is significantly boosting the demand for hemostatic products in this segment. Surgeons require agents that can provide rapid hemostasis and minimize the risk of complications, leading to an increased preference for advanced sealing and hemostatic technologies. This demand for innovative solutions in neurosurgery is anticipated to contribute greatly to market growth.

Urology:

Urological surgeries, including procedures for kidney stones and prostatectomy, often require effective hemostatic agents to control bleeding and promote recovery. The rising prevalence of urological disorders is a significant factor driving the demand for hemostatic solutions in this application segment. Urologists increasingly rely on advanced products that can provide effective hemostasis while ensuring minimal invasiveness. The growing awareness of the benefits of using hemostatic agents in urological procedures is expected to drive market growth further, as healthcare providers aim to improve patient outcomes and reduce complications associated with surgery.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for hemostatic and tissue sealing agents, accounting for a significant share of the market. The increasing number of surgical procedures conducted in hospitals drives the demand for advanced hemostatic solutions, as healthcare providers seek to minimize blood loss and enhance patient safety. The availability of a wide range of hemostatic products within hospital settings ensures that surgeons have access to effective solutions tailored to various surgical applications. Furthermore, the growing investments in healthcare infrastructure and surgical advancements within hospitals are contributing to the sustained growth of this distribution channel.

Specialty Clinics:

Specialty clinics are gaining prominence as a distribution channel for hemostatic agents, particularly in fields such as dermatology, orthopedics, and urology. These clinics often focus on specific surgical and non-surgical procedures, creating a demand for targeted hemostatic solutions that cater to their unique needs. The increasing trend of outpatient surgeries and the rise of specialty clinics offering advanced procedures are expected to boost the adoption of hemostatic products in this segment. As patient preferences shift towards specialized care, the role of specialty clinics as a distribution channel for hemostatic agents is anticipated to grow significantly.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming an important distribution channel for hemostatic and tissue sealing agents, driven by the increasing number of outpatient surgeries. These facilities often perform minimally invasive procedures that require effective hemostatic solutions to control bleeding and facilitate quick recovery. The growing patient shift towards ASCs for their cost-effectiveness and convenience is propelling the demand for hemostatic agents within this channel. As surgical techniques evolve and the focus on patient-centered care intensifies, ASCs are likely to play a crucial role in the distribution of hemostatic products in the market.

Online Sales:

The online sales channel for hemostatic agents is witnessing steady growth as healthcare providers increasingly turn to e-commerce platforms for procurement. The convenience and efficiency of online purchasing, along with the availability of a wide range of products, are driving the adoption of this distribution channel. Additionally, the rising trend of telemedicine and remote healthcare services is contributing to the growth of online sales in the hemostatic agents market. However, strict regulations and the need for product validation pose challenges for online sales, which manufacturers and distributors must navigate to capitalize on this growing trend.

By Ingredient Type

Thrombin:

Thrombin-based hemostatic agents are widely used in surgical settings due to their ability to promote rapid clot formation and control bleeding effectively. These agents work by catalyzing the conversion of fibrinogen to fibrin, leading to the formation of a stable blood clot. The increasing prevalence of surgeries and the growing emphasis on effective blood management are driving the demand for thrombin-based products. Additionally, innovations in thrombin formulations, including recombinant thrombin, are enhancing the efficacy and safety of these agents, making them a preferred choice among healthcare professionals for managing bleeding during procedures.

Gelatin:

Gelatin-based hemostatic agents are derived from collagen and are recognized for their biocompatibility and effectiveness in promoting hemostasis. These agents come in various forms, such as sponges and films, that can be applied directly to bleeding sites to facilitate clot formation. The rising demand for biologically derived products in surgical procedures is significantly driving the gelatin segment. Moreover, the versatility of gelatin in use across different surgical specialties enhances its market appeal. As healthcare professionals increasingly prioritize effective solutions for managing bleeding, gelatin-based products are expected to experience significant growth in adoption.

Fibrin Sealants:

Fibrin sealants, composed of fibrinogen and thrombin, are used to promote hemostasis by mimicking the natural clotting process. These products are particularly valuable in surgeries where conventional hemostatic methods may be insufficient. The versatility of fibrin sealants in various surgical applications, including cardiovascular and orthopedic surgeries, contributes to their growing popularity. The increasing focus on minimizing complications and enhancing patient safety in surgical settings drives the demand for fibrin sealants. Furthermore, continuous advancements in formulation and delivery methods are expected to boost the adoption of these agents in the market.

Cyanoacrylate:

Cyanoacrylate adhesives offer a unique solution for hemostasis and tissue sealing due to their rapid adhesion properties. These agents are particularly beneficial in situations requiring quick wound closure and bleeding control. The increasing trend towards minimally invasive surgeries is propelling the use of cyanoacrylate-based products as they provide effective solutions for closing incisions without the need for sutures. The growing emphasis on reducing patient recovery times and minimizing postoperative complications further enhances the demand for cyanoacrylate adhesives in surgical settings. As healthcare professionals seek reliable and efficient solutions for managing bleeding, cyanoacrylate products are likely to witness significant growth in adoption.

Collagen:

Collagen-based hemostatic agents are gaining traction due to their natural properties and ability to promote wound healing. These agents facilitate hemostasis by providing a scaffold for platelets and enhancing the coagulation process. The increasing awareness regarding the benefits of using collagen products in surgical procedures, coupled with the growing prevalence of surgeries, is greatly driving the demand for collagen-based agents. Furthermore, advancements in collagen processing technology are leading to the development of more effective formulations that cater to the specific needs of various surgical applications. As healthcare professionals continue to prioritize effective bleeding management, collagen hemostatic agents are becoming an increasingly attractive option in surgical practice.

By Region

In North America, the hemostatic and tissue sealing agents market is poised for substantial growth, driven by the increasing volume of surgical procedures and a strong focus on advanced medical technologies. The market in this region is projected to achieve a CAGR of around 7.5% between 2025 and 2035, with the United States being the primary contributor owing to its well-established healthcare infrastructure and high surgical volumes. The rising prevalence of chronic diseases necessitating surgical intervention, combined with growing awareness of the benefits of hemostatic agents, is further bolstering market growth in North America. Moreover, key players in the region are heavily investing in research and development to innovate and enhance product offerings, creating a highly competitive landscape.

Europe stands as a significant region in the hemostatic and tissue sealing agents market, driven by the increasing aging population and the rising incidence of surgeries. The growth of this region is supported by favorable healthcare policies and a strong emphasis on patient safety and effective wound management. As Europe continues to witness advancements in surgical technologies and innovations in hemostatic products, the market is projected to maintain a steady growth trajectory. Additionally, the expansion of outpatient surgical centers and the increasing inclination towards minimally invasive procedures are expected to further fuel market growth in this region, making it a critical area for industry stakeholders.

Opportunities

The hemostatic and tissue sealing agents market presents numerous opportunities for growth, particularly driven by the increasing trend towards minimally invasive surgical procedures. As healthcare providers continue to focus on enhancing patient outcomes and reducing recovery times, the demand for advanced hemostatic solutions designed for minimally invasive settings is expected to surge. This shift creates a favorable landscape for manufacturers to innovate and introduce new products tailored to meet the unique needs associated with minimally invasive surgeries. Additionally, the growing trend of outpatient procedures offers an opportunity for companies to expand their market reach and cater to the rising demand for effective hemostatic agents in these environments.

Furthermore, the ongoing research and development efforts within the healthcare sector open new avenues for growth in the hemostatic and tissue sealing agents market. Innovations such as smart hemostatic agents that can provide real-time feedback on hemostasis and improved formulations that enhance patient safety are actively being pursued by key players. Collaborations between academic institutions and industry leaders are fostering advancements in product development, leading to the introduction of cutting-edge technologies. As healthcare systems continue to evolve and adapt to the challenges posed by an aging population and increasing surgical demands, the market is poised for significant growth through these innovative opportunities.

Threats

Despite the significant growth prospects in the hemostatic and tissue sealing agents market, several threats could hinder its progress. Regulatory challenges present a major concern, as the stringent approval processes for medical devices can lead to lengthy delays in product launches. Companies must navigate complex regulatory environments to ensure compliance with safety standards and gain market authorization for their products. Additionally, the presence of alternative wound management solutions and traditional methods such as sutures may pose a challenge to the adoption of advanced hemostatic agents. Healthcare professionals may opt for conventional approaches due to familiarity, potentially limiting market penetration for newer products.

Moreover, the competitive landscape in the hemostatic and tissue sealing agents market is intensifying, with numerous players vying for market share. This competition can lead to pricing pressures, impacting profit margins for manufacturers. As companies strive to differentiate their products and capture consumer interest, the risk of product recalls or quality concerns may arise. Ensuring consistent product efficacy and safety is paramount, and any lapses can undermine brand reputation and consumer trust. Therefore, manufacturers must remain vigilant in maintaining high standards for their products while also addressing the challenges posed by a dynamic market environment.

Competitor Outlook

• Johnson & Johnson
• Medtronic
• Baxter International Inc.
• CSL Behring
• Ethicon, Inc.
• Stryker Corporation
• Fresenius Kabi AG
• Hemostasis LLC
• Smith & Nephew
• ConvaTec Group PLC
• Hemostatix
• Admedus
• Sealantis Ltd.
• Advanced Medical Solutions Group plc
• Integra LifeSciences Corporation

The competitive landscape of the hemostatic and tissue sealing agents market is characterized by the presence of several key players striving to enhance their market position through innovation and strategic collaborations. Leading companies like Johnson & Johnson and Medtronic are at the forefront, investing heavily in research and development to introduce innovative hemostatic solutions that cater to evolving surgical needs. The emphasis on product differentiation, driven by advancements in technology and improvements in efficacy, is pushing companies to develop a diverse portfolio of hemostatic agents that can address a wide range of surgical applications.

Moreover, companies are increasingly adopting strategic partnerships and acquisitions to expand their market reach and capabilities. For instance, Baxter International Inc. has been actively collaborating with research institutions to develop cutting-edge hemostatic products that leverage advanced biomaterials and technologies. These collaborations enable companies to leverage external expertise and resources, enhancing their product offerings and accelerating time-to-market for new innovations. The competitive landscape is marked by a focus on addressing the specific needs of healthcare providers, with companies aiming to enhance patient outcomes through safer and more effective hemostatic solutions.

As the market continues to evolve, key players are also prioritizing sustainability and ethical practices in their operations. Companies like Stryker Corporation and Fresenius Kabi AG are increasingly focusing on environmentally friendly manufacturing processes and sustainable product development practices. This commitment to sustainability not only resonates with consumers but also positions these companies favorably in a market that is increasingly valuing corporate responsibility. In conclusion, the hemostatic and tissue sealing agents market presents a dynamic competitive landscape where innovation, collaboration, and sustainability are shaping the strategies of key players.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Admedus
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hemostatix
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 CSL Behring
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Ethicon, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Hemostasis LLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sealantis Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Smith & Nephew
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Fresenius Kabi AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Johnson & Johnson
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 ConvaTec Group PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Stryker Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Baxter International Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Integra LifeSciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Advanced Medical Solutions Group plc
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hemostatic and Tissue Sealing Agents Market, By Application
    • 6.1.1 Cardiovascular Surgery
    • 6.1.2 General Surgery
    • 6.1.3 Orthopedic Surgery
    • 6.1.4 Neurosurgery
    • 6.1.5 Urology
  • 6.2 Hemostatic and Tissue Sealing Agents Market, By Product Type
    • 6.2.1 Topical Hemostats
    • 6.2.2 Adhesives
    • 6.2.3 Sealants
    • 6.2.4 Gelatins
    • 6.2.5 Collagens
  • 6.3 Hemostatic and Tissue Sealing Agents Market, By Ingredient Type
    • 6.3.1 Thrombin
    • 6.3.2 Gelatin
    • 6.3.3 Fibrin Sealants
    • 6.3.4 Cyanoacrylate
    • 6.3.5 Collagen
  • 6.4 Hemostatic and Tissue Sealing Agents Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Hemostatic and Tissue Sealing Agents Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hemostatic and Tissue Sealing Agents market is categorized based on

By Product Type

• Topical Hemostats
• Adhesives
• Sealants
• Gelatins
• Collagens

By Application

• Cardiovascular Surgery
• General Surgery
• Orthopedic Surgery
• Neurosurgery
• Urology

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Online Sales

By Ingredient Type

• Thrombin
• Gelatin
• Fibrin Sealants
• Cyanoacrylate
• Collagen

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Medtronic
• Baxter International Inc.
• CSL Behring
• Ethicon, Inc.
• Stryker Corporation
• Fresenius Kabi AG
• Hemostasis LLC
• Smith & Nephew
• ConvaTec Group PLC
• Hemostatix
• Admedus
• Sealantis Ltd.
• Advanced Medical Solutions Group plc
• Integra LifeSciences Corporation